Similar articles

• Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.

  Tuong CC, Ferrand C, Aubert D, Loubrie JC, Tuong A. Tuong CC, et al. Biochem Pharmacol. 1982 Mar 15;31(6):1147-50. doi: 10.1016/0006-2952(82)90355-0. Biochem Pharmacol. 1982. PMID: 7200772 No abstract available.
• Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.

  Maeda K, Usuda M, Kawaguchi S, Shinzato T, Saito A, Ohta K, Kobayashi K, Ohbayashi S, Narita M. Maeda K, et al. Artif Organs. 1980 Feb;4(1):30-3. doi: 10.1111/j.1525-1594.1980.tb03897.x. Artif Organs. 1980. PMID: 7369892
• Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats.

  Ashida S, Ishihara M, Ogawa H, Abiko Y. Ashida S, et al. Thromb Res. 1980 Apr 1-15;18(1-2):55-67. doi: 10.1016/0049-3848(80)90170-x. Thromb Res. 1980. PMID: 7404505 No abstract available.
• Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.

  Picard-Fraire C. Picard-Fraire C. Thromb Res Suppl. 1983;4:119-28. doi: 10.1016/0049-3848(83)90367-5. Thromb Res Suppl. 1983. PMID: 6356462 Review.
• [Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].

  Breitkreutz J. Breitkreutz J. Pharm Unserer Zeit. 2009;38(4):330-7. doi: 10.1002/pauz.200900322. Pharm Unserer Zeit. 2009. PMID: 19572353 Review. German. No abstract available.